AU Stock MarketDetailed Quotes

CUV Clinuvel Pharmaceuticals Ltd

Watchlist
  • 11.840
  • +0.230+1.98%
20min DelayTrading Mar 19 15:14 AET
592.72MMarket Cap16.96P/E (Static)

Clinuvel Pharmaceuticals Ltd Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Clinuvel Pharmaceuticals Ltd H1 FY2025 Earnings Date

Currency：AUDFeb 27, 2025

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
35.30M
35.65M
+345.88K
Beat Est.
+9.43%
+10.51%
+0.98%
EPS
0.23
0.28
+0.05
Beat Est.
+9.91%
+32.08%
+20.17%
Analyst Rating
Strong Buy

Mar 1, 2025

Clinuvel Pharmaceuticals Ltd Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: AUD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/H2-- / 60.800M--
Feb 27, 20252025/H135.646M / 35.300M--
Aug 29, 20242024/H255.921M / 55.100M--
Feb 22, 20242024/H132.257M / 34.433M--
Aug 29, 20232023/H248.966M / 46.300M--
DatePeriodRevenue/EstimateEarnings Call
--2025/H2-- / 60.800M--
Feb 27, 20252025/H135.646M / 35.300M--
Aug 29, 20242024/H255.921M / 55.100M--
Feb 22, 20242024/H132.257M / 34.433M--
Aug 29, 20232023/H248.966M / 46.300M--

Unlock Free Earnings Estimates

Clinuvel Pharmaceuticals Ltd Earnings Reports

  • Clinuvel Pharmaceuticals Ltd: CLINUVEL Investor Webinar

    Feb 27 17:06 ET

  • Clinuvel Pharmaceuticals Ltd: Half Year Results Presentation

    Feb 26 18:48 ET

  • Clinuvel Pharmaceuticals Ltd: Half Year Results Announcement

    Feb 26 18:47 ET

  • Clinuvel Pharmaceuticals Ltd: Appendix 4D and Half Year Report

    Feb 26 18:42 ET

    • Read more

    Trending Stocks
    ASX High Dividend ASX High Dividend
    Symbol Div YieldTTM Dividend TTM
    Telstra Group Ltd
    TLS
    4.26% 0.18
    Westpac Banking Corp
    WBC
    4.87% 1.47
    National Australia Bank Ltd
    NAB
    5.15% 1.68
    BHP Group Ltd
    BHP
    6.03% 2.39
    Woodside Energy Group Ltd
    WDS
    9.10% 2.08

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Mar 1, 2025

    Strong Buy

    • Strong Buy

      87.50%

    • Buy

      12.50%

    • Hold

      0.00%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Investment Theme Healthcare - Cancer Research
    Healthcare - Cancer Research
    Intraday+0.85%